Intussusception and Rotavirus Vaccines

Consensus on Benefits Outweighing Recognized Risk

Jim P. Buttery, MB BS, MD, MSc; Jane Standish, MB BS, FRACP; Julie E. Bines, MB BS, MD, FRACP


Pediatr Infect Dis J. 2014;33(7):772-773. 

In This Article

Abstract and Introduction


Since licensure in 2006, the rotavirus vaccines, RV5 (pentavalent bovine-human reassortant vaccine, Rotateq, Merck) and RV1 (attenuated monovalent human rotavirus vaccine, Rotarix, GSK Biologicals), have reduced morbidity and mortality from acute gastroenteritis in young children. Consensus on these vaccines having a small increased risk of intussusception after the first 1 or 2 doses has slowly emerged, with the risk benefit equation strongly favoring benefit in both developed and developing settings.